Shares of Pliant Therapeutics Inc. (NASDAQ: PLRX) traded at a new 52-week high today and are currently trading at $24.47. So far today, approximately 420.82k shares have been exchanged, as compared to an average 30-day volume of 315.02k shares.
Pliant Therapeutics Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1.
Pliant Therapeutics Inc. share prices have moved between a 52-week high of $24.81 and a 52-week low of $3.96. The stock has moved 17.13% over the past week.
To learn more about Pliant Therapeutics Inc., visit the company’s website at https://pliantrx.com.
Receive IBN Spotlights – “Bite Size” Small, Mid and Large-Cap Technical Indicator Alerts
To stay connected with our complimentary IBN Spotlights, please visit https://IBN.fm/connected
About IBN (InvestorBrandNetwork)
IBN consists of 50+ trusted financial brands introduced to the investment public over the course of 15+ years. Through these brands, IBN provides (1) access to our Investor Press Release Wire Solutions via InvestorWire (IW) to reach all target markets, industries and demographics in the most effective manner possible; (2) article and Code Editorial Syndication to 5,000+ broadcast outlets; (3) enhanced press release solutions via IW to ensure maximum impact; (4) full-scale distribution to an enormous social media audience that includes millions of followers; and (5) a full array of corporate communications solutions focused on the IBN Podcast Series. With a proven track record serving 500+ client partners, IBN is the key to a more effective market communication campaign and the NEW normal.
For more information on IBN, please visit https://www.InvestorBrandNetwork.com